Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A.
Ravandi F, et al. Among authors: kye s.
Blood Adv. 2023 Nov 14;7(21):6492-6505. doi: 10.1182/bloodadvances.2023010956.
Blood Adv. 2023.
PMID: 37647601
Free PMC article.
Clinical Trial.